EMA/290659/2016

European Medicines Agency decision

P/0139/2016

of 20 May 2016

on the agreement of a paediatric investigation plan and on the granting of a deferral for doravirine (EMEA-001676-PIP01-14) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Contact EMA www.ema.europa.eu/contact

An agency of the European Union

European Medicines Agency decision

P/0139/2016

of 20 May 2016

on the agreement of a paediatric investigation plan and on the granting of a deferral for doravirine (EMEA-001676-PIP01-14) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Merck Sharp & Dohme (Europe), Inc. on 10 October 2014 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 1 April 2016, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for doravirine, tablet, granules, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for doravirine, tablet, granules, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Merck Sharp & Dohme (Europe), Inc., Clos du Lynx, 5, B-1200 - Brussels

Belgium.

Done at London, 20 May 2016

For the European Medicines Agency
Zaïde Frias
Head of Division
Human Medicines Research and Development Support
(Signature on file)

EMA/PDCO/34468/2016
London, 1 April 2016

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMEA-001676-PIP01-14

Scope of the application

Active substance(s):

Doravirine

Condition(s):

Treatment of human immunodeficiency virus type 1 (HIV-1) infection

Pharmaceutical form(s):

Tablet

Granules

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Merck Sharp & Dohme (Europe), Inc.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5510
Send a question via our website www.ema.europa.eu/contact

An agency of the European Union

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Merck Sharp & Dohme (Europe), Inc. submitted for agreement to the European Medicines Agency on 10 October 2014 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 19 November 2014.

Supplementary information was provided by the applicant on 17 December 2015.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable.

2. Paediatric investigation plan

2.1. Condition:

Treatment of human immunodeficiency virus type 1 (HIV-1) infection.

2.1.1. Indication(s) targeted by the PIP

Antiretroviral therapy, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in children aged from birth to 18 years.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Tablet

Granules

2.1.4. Measures

Area	**Number of measures**	**Description**
Quality-related studies	1	**Study 1** Development of an age-appropriate oral solid dosage form.
Non-clinical studies	2	**Study 2** Dose range-finding juvenile toxicity study **Study 3** Definitive juvenile toxicity study
Clinical studies	6	**Study 4** Open-label two periods trial to evaluate pharmacokinetic, safety, and activity, of doravirine and doravirine fixed dose combination with lamivudine and tenofovir disoproxil fumarate in children from 12 to less than 18 years of age with HIV-1 infection **Study 5** Open-label two periods trial to evaluate pharmacokinetic, safety and activity, of doravirine and doravirine fixed dose combination

		with lamivudine and tenofovir disoproxil fumarate in paediatric patients from 2 to less than 12 years of age with HIV-1 infection **Study 6** Open-label two phase trial to evaluate pharmacokinetic, safety and activity, of doravirine in paediatric patients from 1 month to less than 2 years of age with HIV-1 infection **Study 7** Open-label two phase trial to evaluate pharmacokinetic, safety and activity of doravirine in children from birth to six weeks of age born to HIV infected mothers **Study 8** Relative bioavailability study with doravirine oral granules in healthy adults **Study 9** Relative bioavailability study with doravirine age appropriate granules in healthy adults
Extrapolation, modelling and simulation studies	1	**Study 10** Pharmacokinetic modelling and simulation study to evaluate appropriate dose of doravirine in children from birth to less than 18 years of age with HIV infection
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By January 2024.
Deferral for one or more measures contained in the paediatric investigation plan:	Yes